实用器官移植电子杂志
實用器官移植電子雜誌
실용기관이식전자잡지
Practical Journal of Organ Transplantation (Electronic Version)
2013年
6期
333-338
,共6页
万平%夏强%张建军%李齐根%徐宁%张明%陈小松%韩龙志
萬平%夏彊%張建軍%李齊根%徐寧%張明%陳小鬆%韓龍誌
만평%하강%장건군%리제근%서저%장명%진소송%한룡지
肝移植%肝癌%活体
肝移植%肝癌%活體
간이식%간암%활체
Liver transplantation%Liver cancer%Live donor
目的基于单中心的中长期随访结果,探讨活体肝移植治疗原发性肝癌的疗效及优势。方法回顾性总结2007年5月至2011年4月在上海仁济医院肝脏外科行活体肝移植的原发性肝癌患者的临床资料、围手术期数据、并发症情况以及中长期随访结果。结果41例患者的乙肝表面抗原均为阳性;患者中男性35例(85.4%),女性6例(14.6%);中位年龄50(28~66)岁;所有患者都进行活体肝移植,术后病理确诊为原发性肝癌;其中3例(7.3%)为挽救性肝移植,13例(31.7%)患者在肝移植前接受术前降期治疗;符合米兰标准的患者为24例(58.5%),17例超米兰标准(41.5%)。术后并发症包括感染13例(31.7%)、胆道并发症11例(26.8%)、血管并发症1例(2.4%)、腹腔内出血1例(2.4%)、多器官功能障碍综合征(MODS)1例(2.4%)、高血压1例(2.4%)、精神症状1例(2.4%)、切口液化3例(7.3%)和切口裂开1例(2.4%),1例患者发生围手术期死亡(2.4%)。术后1年和5年累积总生存率分别为90.1%和72.3%,1年和5年累积复发率分别为20.9%和29.0%。24例符合米兰标准与17例超米兰标准患者的1年和5年生存率分别为91.7%比87.5%和83.1%比56.3%(P=0.051),1年和5年累积复发率分别为13.0%比32.7%和17.4%比47.0%(P=0.035)。结论活体肝移植治疗原发性肝癌能取得良好的近远期手术疗效。
目的基于單中心的中長期隨訪結果,探討活體肝移植治療原髮性肝癌的療效及優勢。方法迴顧性總結2007年5月至2011年4月在上海仁濟醫院肝髒外科行活體肝移植的原髮性肝癌患者的臨床資料、圍手術期數據、併髮癥情況以及中長期隨訪結果。結果41例患者的乙肝錶麵抗原均為暘性;患者中男性35例(85.4%),女性6例(14.6%);中位年齡50(28~66)歲;所有患者都進行活體肝移植,術後病理確診為原髮性肝癌;其中3例(7.3%)為輓救性肝移植,13例(31.7%)患者在肝移植前接受術前降期治療;符閤米蘭標準的患者為24例(58.5%),17例超米蘭標準(41.5%)。術後併髮癥包括感染13例(31.7%)、膽道併髮癥11例(26.8%)、血管併髮癥1例(2.4%)、腹腔內齣血1例(2.4%)、多器官功能障礙綜閤徵(MODS)1例(2.4%)、高血壓1例(2.4%)、精神癥狀1例(2.4%)、切口液化3例(7.3%)和切口裂開1例(2.4%),1例患者髮生圍手術期死亡(2.4%)。術後1年和5年纍積總生存率分彆為90.1%和72.3%,1年和5年纍積複髮率分彆為20.9%和29.0%。24例符閤米蘭標準與17例超米蘭標準患者的1年和5年生存率分彆為91.7%比87.5%和83.1%比56.3%(P=0.051),1年和5年纍積複髮率分彆為13.0%比32.7%和17.4%比47.0%(P=0.035)。結論活體肝移植治療原髮性肝癌能取得良好的近遠期手術療效。
목적기우단중심적중장기수방결과,탐토활체간이식치료원발성간암적료효급우세。방법회고성총결2007년5월지2011년4월재상해인제의원간장외과행활체간이식적원발성간암환자적림상자료、위수술기수거、병발증정황이급중장기수방결과。결과41례환자적을간표면항원균위양성;환자중남성35례(85.4%),녀성6례(14.6%);중위년령50(28~66)세;소유환자도진행활체간이식,술후병리학진위원발성간암;기중3례(7.3%)위만구성간이식,13례(31.7%)환자재간이식전접수술전강기치료;부합미란표준적환자위24례(58.5%),17례초미란표준(41.5%)。술후병발증포괄감염13례(31.7%)、담도병발증11례(26.8%)、혈관병발증1례(2.4%)、복강내출혈1례(2.4%)、다기관공능장애종합정(MODS)1례(2.4%)、고혈압1례(2.4%)、정신증상1례(2.4%)、절구액화3례(7.3%)화절구렬개1례(2.4%),1례환자발생위수술기사망(2.4%)。술후1년화5년루적총생존솔분별위90.1%화72.3%,1년화5년루적복발솔분별위20.9%화29.0%。24례부합미란표준여17례초미란표준환자적1년화5년생존솔분별위91.7%비87.5%화83.1%비56.3%(P=0.051),1년화5년루적복발솔분별위13.0%비32.7%화17.4%비47.0%(P=0.035)。결론활체간이식치료원발성간암능취득량호적근원기수술료효。
Objective To evaluate the therapeutic effect and benefit achieved on patients with hepatic carcinoma after live donor liver transplantation (LDLT)based on medium- and long-term follow-up experience. Methods Patients who underwent LDLT for primary hepatic carcinoma between May 2007 and April 2011 in the Department of Liver Surgery of Ren Ji Hospital in Shanghai were enrolled into this study,the clinical pathological data,perioperative outcomes,postoperative complications and follow-up results were retrospectively reviewed from liver transplantation database. Results From May 2007 to April 2011,there were a total of 41 patients with pathologically proven primary hepatic carcinoma underwent LDLT in our center,with 35 males(85.4%) and 6 females(14.6%),mean age of 50(28-66)years. All of the patients underwent LDLT,and were diagnosed with primary liver cancer by pathology. Salvage LDLT was performed in 3 patients(7.3%),and 13 cases(31.7%)received downstaging before LDLT. 24 of them(58.5%)met the Milan criteria,and 17 case(41.5%)exceeded the criteria. Postoperative complications happened in this group of patients included postoperative infections(13 cases,31.7%),biliary complications(11 cases, 26.8%), vascular complications(1 case, 2.4%), intra-abdominal bleeding (1 case,2.4%),multiple organ dysfunction syndrome(MODS,1 case,2.4%),hypertension(1 case,2.4%),mental symptom(1 case,2.4%),wound infection(3 cases,7.3%)and wound dehiscence(1 case,2.4%). Perioperative death occurred in 1 patient(2.4%). Overall 1- and 5-year cumulative survival rates were 90.1% and 72.3%, respectively;and 1-and 5-year cumulative recurrence rates were 20.9%and 29.0%,respectively. 1-and 5-year survival rates in 24 cases meeting Milan criteria and 17 exceeding Milan criteria were 91.7%vs. 87.5%and 83.1%vs. 56.3%(P=0.051);and 1-and 5-year cumulative survival rates were 13.0%vs. 32.7%and 17.4%vs. 47.0%(P=0.035) Conclusion Patients with primary hepatic carcinoma could achieve favorable outcomes after LDLT.